Jeremy Wyatt

Jeremy Wyatt is the CEO of ActiGraph, a leading global provider of physical activity and sleep monitoring solutions for pharmaceutical and academic industries. With two decades of embedded hardware systems development and related cloud technology expertise, Jeremy has a uniquely well-rounded perspective on the challenges and opportunities of deploying wearable technologies to capture accurate and meaningful patient data. He is considered an industry thought leader and expert in the clinical biosensor space and is a frequent representative and contributor at clinical drug development commercial events, scientific consortiums and FDA/EMA regulatory meetings. He has an undergraduate degree in electrical engineering from the University of Florida and an MBA from the University of West Florida. Jeremy is a member and contributor to the Digital Medicine (DiMe) Society and participates in various digital biomarker efforts with the Clinical Trial Transformation Initiative (CTTI).

Reflecting on a Year of Transformative Advancements in Digital Health

As we embark on another exciting year for the digital health landscape, I wanted to take a moment...

Frequently Asked Questions: ActiGraph GT9X Link

As of August 23, 2023, ActiGraph discontinued the sale of new GT9X Link wearable digital health...

ActiGraph No Longer Selling New GT9X Link Wearable Devices

Effective August 23, 2023, new GT9X Link wearable devices will no longer be available for purchase....

ActiGraph's Reimagined Logo, Website, and Mission Statement

At ActiGraph, we're proud of our history of partnering with clinical researchers around the world,...

Bridging the Knowledge Gap on Digital Clinical Measures: A Technology Partner’s Perspective on ‘The Playbook’

ActiGraph was one of the very first commercial providers of wearable motion-sensing technology,...